Pharmaceutical Executive is proud to announce that it has been awarded a 2022 APEX Award of Excellence for its Pharmaceutical Executive Podcast.
The Pharm Exec podcast, which debuted in 2018, features interesting and engaging c-suite-level leaders in the pharma, biopharma, and biotech space who can share unique, helpful, and non-promotional business insights with the intention of helping educate, inspire, and enlighten their fellow leaders. Currently up to 112 biweekly episodes and counting, the podcast is co-hosted by Editor-in-Chief, Elaine Quilici, and Group Social Media Editor, Miranda Schmalfuhs. Pharm Exec would also like to recognize the podcast’s original co-hosts, Christen Harm and Michelle Maskaly.
For more information on the Pharm Exec podcast and how to get involved, read the FAQs in the following link.
PE Podcast FAQsThe APEX Awards are based on excellence in graphic design, editorial content, and the ability to achieve overall communications excellence. APEX Grand Awards honor the outstanding works in each main category, while APEX Awards of Excellence recognize exceptional entries in each of the individual subcategories. After more than 1,200 entries, 100 Grand Awards were presented to work in 14 major categories, and 485 Awards of Excellence in 100 subcategories.
The panel of judges for APEX 2022 included Ken Turtoro, APEX Senior Judge and Concepts Executive Editor; John De Lellis, Concepts Editor & Publisher; Christine Turner, Contributing Editor of the Writing That Works Archives; and John Tavaska, Consulting Editor.
To view the full list of APEX entries, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.